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Background: The optimal laboratory assay for detecting KRAS mutations in different biospecimens from patients
with metastatic colorectal cancer (mCRC), and the clinical relevance of these gene alterations is still in question.
We analyzed the prognostic–predictive relevance of KRAS status, determined in tumor and plasma DNA by two
different assays, in a large mono-institutional series of mCRC patients.
Methods: DNA sequencing and peptide-nucleic-acid-mediated-polymerase chain reaction clamping (PNA-PCR) were
used to determine KRAS status in 416 tumor and 242 matched plasma DNA samples from mCRC patients who received
chemotherapy only. Relationships with outcomes were analyzed with respect to the different assays and tissue types.
Results: PNA-PCR was significantly more sensitive in detecting KRAS mutations than sequencing (41% vs. 30%,
p < 0.001). KRAS mutations were more frequent in tumor tissue than in plasma (sequencing, 38% vs. 17%, p < 0.001;
PNA-PCR, 47% vs. 31%, p < 0.001). Median OS was consistently shorter in KRAS-mutated patients than KRAS
wild-type patients, independent from the assay and tissue tested; the largest difference was in plasma samples
analyzed by PNA-PCR (KRAS mutated vs. wild-type: 15.7 vs. 19.1 months, p = 0.009). No association was observed
between KRAS status and other outcomes. When tumor and plasma results were considered together, median OS in
patients categorized as tissue/plasma KRAS negative/negative, tissue/plasma KRAS discordant, and tissue/plasma KRAS
positive/positive were 21.0, 16.9 and 15.4 months, respectively (p = 0.008).
Conclusions: KRAS mutation status is of prognostic relevance in patients with mCRC. KRAS mutations in both tumor
tissue and plasma are a strong prognostic marker for poor outcomes.
Keywords: Kras, Colorectal cancer, PrognosisBackground
K-RAS is a key oncogene member of the mitogen-activated
protein kinase signaling pathway [1,2]. Research primarily
in colorectal cancer shows that KRAS mutations occur
most commonly in codons 12 and 13, usually precede the
development of malignancy [3,4], and are maintained in
secondary disease sites [5].* Correspondence: jmxu2003@yahoo.com
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unless otherwise stated.Several studies have addressed the prognostic-predictive
value of KRAS mutational status in colorectal cancer pa-
tients [6]. It is now well established that KRAS mutations
are the main reason for resistance to anti-epidermal
growth factor receptor (EGFR) antibodies [7,8], and ac-
count for nearly two-thirds of EGFR downstream effector
alterations in colorectal cancer [9]. KRAS mutations are
also a predictive factor for response to tyrosine kinase in-
hibitors [10].
Clinical data regarding the prognostic value of KRAS
mutations in patients with metastatic colorectal cancer
(mCRC) treated with chemotherapy remain inconclusive
[1]. Most studies addressing this question were retro-
spective or included limited patient numbers [6]. SomeThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[11] because the data were derived from the control arm
of randomized trials of anti-EGFR antibodies as first-line
treatment in combination with chemotherapy. In these
studies, cross-over to anti-EGFR therapy was permitted or
patients received anti-EGFR therapy after study treatment,
making prognostic interpretation difficult. The prognostic-
predictive relevance of KRAS alterations to chemotherapy
alone in mCRC has still to be determined in a large patient
sample.
Although direct sequencing is widely accepted as the
gold standard for mutation screening [12], this method re-
quires that ≥25% of DNA alleles in the sample are mutated
[6,13]. Over the past five years, several new techniques,
including peptide-nucleic-acid-mediated polymerase chain
reaction clamping (PNA-PCR), have emerged. These
methods have higher sensitivity than direct sequencing,
and permit the detection of lower mutation frequencies
(1%-5%) [14-16].
Routine assessment of KRAS mutational status is
generally performed in tumor samples and used to
personalize treatment in patients with mCRC [14,17].
Oh et al. combined PNA-Mediated Asymmetric PCR with
Melting Curve Analysis to detect several types of low-level
KRAS mutations in colorectal cancer tissues [18]. How-
ever, a recent review of 11 clinical studies, reported that
29%-100% of patients presented with the same KRAS
mutation in both blood and tumor samples suggesting
that blood samples may also be suitable for determining
KRAS status [19-21]. One study performed by Yu et al.
has showed that PNA-PCR powered by pyrosequencing
had the potenial to screen plasma KRAS mutations
with high sensitivity and accuracy in pancreatic cancer
patients [22].
We hypothesized that KRAS mutation status deter-
mined using PNA-PCR in tumor tissue and/or blood
could be a powerful and easy-to-perform approach for
planning treatment in patients with advanced colorectal
cancer. In the present study, we analyzed the impact of
KRAS status, determined by both direct sequencing and
PNA-PCR methods in tumor and matched plasma sam-
ples, on clinical outcome in a large consecutive mono-
institutional series of advanced colorectal cancer patients.
All patients received oxaliplatin-based or irinotecan-based
chemotherapy as first-line and second-line treatment, but
never received biologic therapy.
Methods
Study design
Between January 2007 and June 2011, 566 consecutive
patients with mCRC were admitted to the Affiliated
Hospital Cancer Center of the Academy of Military
Medical Sciences in Beijing and were treated with sys-
temic chemotherapy. 416 patients meeting the inclusioncriteria were enrolled into this study retrospectively. The
study was approved by the ethical committee of Affiliated
Hospital, Academy of Military Medical Sciences (ID-2011-
91). All patients provide their written informed consent to
participate in this study.
The inclusion criteria were: completion of ≥2 cycles of
oxaliplatin-based or irinotecan-based chemotherapy as
first-line treatment; no anti-EGFR or anti-vascular endo-
thelial growth factor (VEGF) treatment; measurable
disease; adequate follow-up for disease and survival
assessment; adequate tumor tissue and paired plasma
samples (if available) taken before chemotherapy;
tumor specimens with ≥50% tumor cells confirmed by
certified pathologists; and tumor specimens obtained
from surgical resection, colonoscopy biopsy, or metastatic
site biopsy. Written informed consent was obtained from
each patient.
Reasons for excluding patients (n = 150) from the con-
secutive series were: subsequent treatment with anti-EGFR
and/or anti-VEGF antibodies (n = 85); non-measurable dis-
ease (n = 23); received only 1 chemotherapy cycle (n = 11);
inadequate follow-up (n = 9); tumor tissue unavailable (n =
15); <50% tumor cells confirmed by pathologists (n = 4);
and inadequate tumor specimen (n = 3).Tissue samples
Formalin-fixed, paraffin-embedded (FFPE) tumor tissues
were retrieved at room temperature, assessed by sectioning,
and hematoxylin-eosin stained by certified pathologists.
The pathologist was responsible for tissue block selection
and evaluation of neoplastic cellularity. Each evaluation was
confirmed by two pathologists.
Whole blood samples were collected for DNA ex-
traction from each participant before any invasive pro-
cedures or therapy. Five milliliters of peripheral blood
were collected from each participant in a vacutainer
system with lithium-heparin. Plasma was immediately
separated from the cellular fraction by centrifugation
at 1,500 × g for 10 min and, after aliquotation, frozen
at −80°C.
Direct sequencing and PNA-PCR were performed with
tumor and plasma samples to determine KRAS status.DNA extraction and KRAS mutation analysis
Genomic DNA of tumor tissue was extracted using EZNA™
FFPE DNA Kit D3399 (Omega Bio-Tek, Inc, Norcross,
GA, USA). Free plasma was purified by NucleoSpin®
Plasma, N.740900 (Macherey-Nagel GmBH & Co, Düren,
Germany). All DNA samples were stored at −80°C. Since
most KRAS mutations occur at codons 12 or 13 of exon 2,
PCR primers were designed to amplify the corresponding
region. PCR products were purified by EZNA® Cycle Pure
Kit (Omega Bio-Tek, Inc, Norcross, GA, USA).
Table 1 KRAS status analyzed in tumor tissue and plasma
samples by direct sequencing and PNA-PCR assays
Tumor tissue Plasma Total
Assay KRAS status (n = 416) (n = 242) (n = 658)
Wild type 260 (63) 201 (83) 461 (70)
Mutated 156 (38) 41 (17) 197* (30)
Codon 12 118 (28) 30 (12) 148 (22)
Direct sequencing 12 D 50 13 63
12 V 39 10 49
Other 29 7 36
Codon 13 38 (9) 11 (5) 49 (8)
Wild type 221 (53) 166 (69) 387 (59)
Mutated 195 (47) 76 (31) 271* (41)
Codon 12 133 (32) 56 (23) 189 (29)
PNA-PCR 12 D 57 26 83
12 V 46 17 63
Other 30 13 43
Codon 13 62 (15) 20 (8) 82 (12)
Data expressed as n (%).
*p < 0.001.PNA-PCR, peptide-nucleic-acid-mediated polymerase chain
reaction clamping.
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formed with Applied Biosystems® 3100 Genetic Analyzer
(Life Technologies, Carlsbad, CA, USA) according to
manufacturer’s protocol.
All available tumor and plasma samples were tested by
PNA-PCR. Peptide-nucleic-acid (PNA) oligomers are
non-extendable oligonucleotides. In PNA-mediated PCR
clamping, PNA oligomers suppress the amplification of
the complementary sequence because PNA are not sub-
strates for DNA polymerase. The PNA oligomers (with
sequence of CTACGCCACCAGCTC) covered wild-type
codons 12 and 13 of KRAS. The nested PCR system in-
cluded: 50 ng genomic DNA; 25 μL MightyAmp Buffer;
1 μL MightyAmp DNA Polymerase (DR071, TaKaRa Bio
Inc, Shiga, Japan); 0.01 μM KRAS primers; and 0.2 μM
PNA. After initial denaturation at 94°C for 5 min, PCR
amplification consisted of 35 cycles: 94°C for 30 s; 70°C
for 10 s; 56°C for 30 s; and 68°C for 30 s. This was
followed by elongation at 68°C for 5 min with final
cooling at 4°C. The sequences of primer pairs in the
first run were GTGTGACATGTTCTAATATAGTCA
and GAATGGTCCTGCACCAGTAA, while the inner
forward primer ATGTTCTAATATAGTCACATTTTC
and reverse primer GGTCCTGCACCAGTAATATGCA
were used in the second run. The KRAS mutations in the
nested PCR products were detected by subsequent Sanger
sequencing.
Personnel responsible for mutation analysis were blinded
to clinical outcomes. All experiments were performed at
the Affiliated Hospital Pharmacology Laboratory for
Cancer Research, and all the samples were genotyped
twice for quality control purposes.
Statistical analysis
The chi-squared test was used to determine the associ-
ation between baseline characteristics, clinical response
and KRAS status. Kaplan-Meier methods were used to
estimate progression-free survival (PFS, defined as time
between first day of first-line chemotherapy and disease
progression or death from any cause) and overall sur-
vival (OS, defined as time between first day of first-line
chemotherapy and death from any cause or date of last
follow-up). Response was evaluated by the Response
Evaluation Criteria in Solid Tumors. Cox proportional
hazards models were used for multivariate analyses of
baseline characteristics and KRAS mutations related to
OS. In the multivariate Cox proportional hazard regres-
sion model, gender, age, Eastern Cooperative Oncology
Group (ECOG) performance status, metastatic site, and
KRAS status were used as covariates. The association
between KRAS status in tumor tissue and plasma free
DNA was examined by the Kappa test. All statistical tests
were performed using SAS 9·2 software (SAS Institute,
Cary NC, USA).Results
Patient characteristics
A total of 416 patients met the enrollment criteria and
had primary or metastatic tumor samples; 242 patients
had paired plasma DNA samples. The characteristics of
the patients were: 218 men and 198 women; median age
of 56 (range, 26–87) years; and 365 patients (87.7%) had
an ECOG performance status of 0–1. The characteristics
of the study population are shown in Additional file 1:
Table S1.
KRAS mutation analysis
In order to verify the accuracy of the assays in detecting
KRAS mutation status, 658 samples (416 primary tu-
mors; 242 plasma samples) were analyzed by both direct
sequencing and PNA-PCR (Table 1). Overall, PNA-PCR
identified a higher percentage of KRASmutated cases than
direct sequencing (41% and 30%, respectively; p < 0.001).
This difference was evident in tumor tissue (47% and 38%,
respectively; p < 10−8) and plasma samples (31% and 17%,
respectively; p < 10−8). PNA-PCR was able to detect KRAS
mutations in an additional 39 tumor and 35 plasma sam-
ples where direct sequencing failed (Table 1). There were
no cases in which KRAS mutations were detected by
direct sequencing but not PNA-PCR. When KRAS muta-
tions were further characterized by location (i.e. codons
12 or 13), the sensitivity of PNA-PCR was consistently
higher (Table 1).
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In order to ascertain whether plasma KRAS analysis is
predictive of tumor KRAS mutation status, we assessed
DNA samples from both tumor tissue and pre-surgery
plasma of 242 patients (Table 2). Overall, KRAS mutations
were more frequent in tumor than in plasma samples, and
this was independent of the assay; KRAS mutation rates
in tissue versus plasma were 38% vs. 17% with direct se-
quencing (p < 0.001) and 47% vs. 31.4% with PNA-PCR
(p < 0.001) (Table 1). Only a small percentage of patients
showed KRAS mutations in plasma but not in tumor tissue
(5% by either method) (Table 2). The higher frequency of
KRAS mutations in tumor tissue was also evident when dif-
ferent KRASmutation subgroups were considered (Table 1).
Clinical outcomes and prognostic analysis
The median follow-up duration (calculated from the first
day of first-line chemotherapy) was 26.9 (range, 10.0-62.5)
months. Overall, 125 patients (30.0%) achieved a partial
response. The median PFS of all patients was 6.1 (95%
confidence intervals [CI], 4.8-7.5) months and the median
OS was 17.4 (95% CI, 16.0-18.8) months.
We retrospectively analyzed the association between
KRAS status and patient characteristics. There were no
significant differences between gender, ECOG, perform-
ance status (0–1 vs. 2), metastatic site, and second-line
treatment in patients with KRAS wild-type vs. KRAS mu-
tant samples. We also analyzed the association between
KRAS status and clinical outcomes following first-line
chemotherapy (Table 3).
Tumor DNA analysis
There was no significant relationship between clinical
response in patients with and without KRAS mutations;Table 2 Comparison of KRAS status in tumor tissue and




Wild type Mutated Total Kappa p value†
Direct sequencing
Wild-type (%) 138 (57) 63 (26) 201 ·278 <0 · 001
Mutated (%) 11 (5) 30 (12) 41
Total 149 93 242
PNA-PCR PNA-PCR
Wild-Type (%) 113 (47) 53 (22) 166 ·456 <0 · 001
Mutated (%) 12 (5) 64 (26) 76
Total 125 117 242
*Kappa test was used to estimate the concordance of KRAS status between
tumor tissue and plasma samples.
†All Wald statistical tests were two-sided.
PNA-PCR, peptide-nucleic-acid-mediated polymerase chain reaction clamping.this was also true when subsets of patients carrying spe-
cific alterations in codons 12 or 13 were analyzed separ-
ately (data not shown). No significant difference between
PFS in patients with KRAS wild-type vs. KRAS mutant
samples was evident, regardless of whether mutation sta-
tus was determined by direct sequencing (6.1 vs.
5.8 months; p = 0.473) or PNA-PCR (6.2 vs. 5.9 months;
p = 0.360) (Table 3). However, OS was prolonged in pa-
tients with KRAS wild-type vs. KRAS mutant tumor
samples determined by DNA sequencing (18.3 vs.
15.9 months; p = 0.064), and was statistically significant
when mutation status was determined by PNA-PCR
(19.5 vs. 16.9 months; p = 0.025). Figure 1A shows OS
curves according to KRAS mutation status and by codon
in tumor; the worst prognosis was evident in the sub-
group of patients carrying mutations different from V
and D in codon 12.
The multivariate analysis showed that frequency and
type of KRAS mutations was the only covariate, other
than ECOG performance status, that were significantly
associated with OS (ECOG performance status: odds ra-
tio [OR] 3.03, 95% CI 2.21-3.41, p < 0.001; KRAS wild-
type vs. mutated: OR 1.37, 95% CI 1.06-1.70, p < 0.008).
This association was independent of the assay but stron-
ger with PNA-PCR.
Plasma DNA analysis
No relationship between KRAS status in plasma DNA
samples and clinical response (data not shown) or PFS
was observed (Table 3). Median OS was significantly
longer in patients with KRAS wild-type vs. KRAS mutant
samples, in particular when mutation status was deter-
mined by PNA-PCR (19.1 vs. 15.7 months; p = 0.009).
Figure 1B shows OS curves according to KRAS mutation
status and by codon in plasma.
The multivariate analysis demonstrated that the fre-
quency and type of KRAS mutations was the only covari-
ate, other than ECOG performance status, significantly
associated with OS (ECOG performance status: OR 3.06,
95% CI 2.22-3.46, p < 0.001; KRAS wild-type vs. mutated:
OR 1.35, 95% CI 1.05-1.65, p < 0.008). This association
was independent of the laboratory assay but was stron-
ger for PNA-PCR.
Combined analysis of DNA from tumor and plasma
For the analysis of the prognostic impact of KRAS muta-
tion status, we used data from patients for which DNA
from both tumor tissue and plasma were available (n = 242).
Each patient was classified as KRAS positive (i.e. KRAS
mutations in tumor and plasma samples), KRAS negative
(i.e. KRAS wild-type in tumor and plasma samples), or
with discordant KRAS status in tumor and plasma sam-
ples. This analysis was performed using the results ob-
tained with PNA-PCR only.











95% Cl P value* Median
OS (mo)
95% Cl P value*
Tumor
Sequencing Wild-type 260 6·1 4·5-7·7 ·473 18·3 16·2-20·4 ·064
Mutated 156 5·8 3·4-8·2 15·9 14·4-17·4
PNA-PCR Wild-type 221 6·2 4·5-7·9 ·360 19·5 17·2-21·8 ·025
Mutated 195 5·9 4·0-7·8 16·9 15·6-18·2
Plasma
Sequencing Wild-type 201 6·1 5·5-6·6 ·489 18·3 15·9-20·7 ·037
Mutated 41 5·4 4·9-5·8 15·7 9·3-22·1
PNA-PCR Wild-type 166 6·1 5·5-6·7 ·274 19·1 16·8-21·4 ·009
Mutated 76 5·7 5·3-6·1 15·7 13·0-18·4
*Log-rank test. All statistical tests were two-sided.
CI, confidence interval; mo, month; OS, overall survival; PFS, progression-free survival; PNA-PCR, peptide-nucleic-acid-mediated polymerase chain reaction clamping.
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and clinical response or PFS, the analysis of OS showed
a statistically significant association between the three
cohorts (Table 4 and Figure 2). This association was
confirmed in a multivariate analysis (Additional file 2:
Table S2).
Discussion
In spite of the clear role that KRAS alterations play in
the pathogenesis and progression of colorectal cancer,Figure 1 Overall survival by KRAS mutation status in tumor tissue (A)
further details).several aspects concerning their clinical validation re-
main inconclusive or are not yet fully explored [1].
Among them, the role of more sensitive laboratory as-
says for KRAS mutation analysis, the possibility of using
circulating DNA to acquire information on KRAS sta-
tus, and the possible prognostic-predictive value of these
assays. The present study addresses all of these ques-
tions in a large mono-institutional series of patients
for whom colorectal cancer tissue and plasma samples
were available.and plasma (B) samples detected by PNA-PCR (see text for
Table 4 Prognostic value of combined tumor/plasma KRAS
status analyzed by PNA-PCR in a series of 242 metastatic
colorectal cancer patients with matched samples
KRAS status* Median OS
Tumor/Plasma No. (mo) 95% Cl P value
Negative/Negative 113 21.0 19.226-22.774 0.008
Discordant 65 16.9 14.184-19.616
Positive/Positive 64 15.4 14.270-16.530
*KRAS status was categorized as: negative, mutation-negative tumor and
matched plasma samples; discordant, discordant KRAS status in tumor
and matched plasma samples; positive, mutation-positive tumor tissue and
matched plasma samples.
CI, confidence interval; mo, month; OS, overall survival; PNA-PCR, peptide-
nucleic-acid-mediated polymerase chain reaction clamping.
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than direct sequencing, permitting the detection of muta-
tions at frequencies as low as 1%-5% [23]. We performed
658 assays by PNA-PCR and direct sequencing and found
a significantly higher percentage of KRAS gene alterations
with PNA-PCR (41% vs. 30%; p < 0.001), which was inde-
pendent of the sample source (FFPE tumor samples or
frozen plasma). A similar result has been reported in other
studies [24,25] . Further, there were no cases in our study
in which mutations were detected by direct sequencing
but not PNA-PCR. We suggest that PNA-PCR is more ac-
curate than direct sequencing and may be a clinically use-
ful assay.
It has been suggested that circulating DNA is a suit-
able and reliable source of DNA for tumor somatic gene
alterations [26] , but is this the case for the KRAS gene?
In our study, we observed KRAS mutation detectionFigure 2 Prognostic value of KRAS status analysed either in tumor tis
tissue and plasma, KRAS status of each patient was categorized as: negative
(KRAS status discordant in tumor and matched plasma samples); positive (Krates in plasma samples of 17% and 31% by direct sequen-
cing and PNA-PCR, respectively. Recent research indi-
cates that the mutation detection rates in tumor tissue
and plasma are influenced by disease stage [27,28], meta-
static sites and performance status, since the major source
of plasma DNA is from necrotic or apoptotic tumor cells
[26]. Therefore, there would be a greater likelihood of de-
tecting KRAS mutations in patients with a larger tumor
burden or after multiple lines of therapy. Our study popu-
lation was chemotherapy-naïve, which would be expected
to result in a lower detection rate in plasma DNA.
A recent literature review [15] confirmed that KRAS al-
terations in ctDNA from plasma are significantly predictive
of KRAS tumor status with a concordance between tumor
and plasma status ranging from 29% to 100%. We analyzed
242 paired tumor and plasma samples, the largest series
reported to date, and showed that determining KRAS sta-
tus in plasma is feasible and provides information on gene
status concordant with tumor DNA analysis by PNA-PCR
in 73% of cases (Table 2). Although we showed that
PNA-PCR can detect more KRAS mutated cases and that
the discrepancy might be due to cases showing a mutation
in the primary tumor and not in plasma, and this fact is in
agreement with other recent studies which addressed the
same question [29,30], further optimization of this methods
also might increase the concordance between tumor and
plasma as the investigation of KRAS and BRAF mutations
consistence in tumor tissue and cfDNA [31]. We also found
that 5% of cases that are mutant in plasma but wide-type in
the tissue with both methods. The reasonable explanation
for this is the heterogenity of cancer tissue, which meanssue or plasma samples by PNA-PCR. According to analyses of tumor
(KRAS wild type in tumor and matched plasma samples), discordant,
RAS mutated either in tumor tissue and matched plasma samples.
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part of the tumor and did not contain the DNA carrying
KRAS mutations that released into blood from other parts
of tumor. Our study indicates that, if a tumor sample is un-
available or insufficient, using a more sensitive method than
PNA-PCR assay such as ultra deep sequencing technology
on a plasma DNA sample might be an alternative way to
determine KRAS status in metastatic colorectal cancer.
The prognostic-predictive value of KRAS mutations in
mCRC remains controversial. Recently, Ren et al. [6] did
a systematic review and meta-analysis on this topic and
identified 13 studies which showed that KRAS mutations
are significantly associated with OS, but no separate ana-
lysis for studies in metastatic disease was performed.
Yokota [32] also did not consider mCRC separately. How-
ever, Loriot [1] reviewed 6 clinical studies specifically
looking at KRAS status in stage IV colorectal cancer and
reported that KRAS mutations have no predictive value
with conventional chemotherapy. Our results confirm these
observations. KRAS status, and KRAS mutations in codons
12 or 13, had no predictive relevance for clinical response
to chemotherapy or PFS. This finding was independent of
assay utilized and DNA source. The conclusions were dif-
ferent when OS was considered. OS was influenced by
KRAS status analyzed by PNA-PCR in plasma free DNA
(univariate analysis, 15.7 months for KRAS mutations vs.
19.1 months for KRAS wild-type; p < 0.009; multivariate
analysis, OR 1.35, 95% CI 1.05-1.65, p < 0.008). Interest-
ingly, patients with KRAS mutations, regardless of their
location, had a poorer prognosis than KRAS wild-type pa-
tients (Figure 1), although the differences between them
were not significantly different. Overall, our results seem
to confirm that KRAS mutations are associated with a
more aggressive form of colorectal cancer.
It is difficult to compare our results with previous
studies, as few studies have differentiated between KRAS
mutations at codon 12 and 13. The largest study on this
topic, RASCAL II which involved 3439 colorectal cancer
patients, concluded that different gene mutations have dif-
ferent impacts on outcome, and in particular the codon 12
glycine to valine mutation, but it did not look specifically
at stage IV disease [33]. Only one study [34] has consid-
ered advanced disease treated with systemic chemotherapy
and showed that only the OS of patients carrying KRAS
codon 13 mutations was significantly worse than for pa-
tients with wild-type KRAS. We further demonstrated that
the impact of KRAS status on OS is independent from
assay and DNA source, thus reinforcing the reliability
of the evidence.
When patients were divided according to their com-
bined plasma/tissue KRAS status, the best prognosis was
observed in patients without mutations in either tumor or
plasma, while the worst was evident in patients with mu-
tations in both tissues. The subgroup with a discordantKRAS status showed an intermediate long-term prognosis.
The prognostic relevance of this classification was con-
firmed in the multivariate analysis. The biological implica-
tions of this observation are unknown, but it seems possible
that DNA from both primary tumor and plasma (which
includes DNA from different sites) may provide additional
clinically relevant information.
Conclusion
This study showed that KRAS mutation status is able to
predict long-term prognosis of patients with mCRC treated
with conventional chemotherapy. This association was in-
dependent of the type of biospecimen and assay utilized
for KRAS analysis, indicating that plasma DNA samples
may provide an alternative biological source for KRAS
mutation analysis. Further studies are required to corrob-
orate this last hypothesis.
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